Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5903.09 | 1.0130 | 1.0280 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5903.09 | 0.9974 | 0.9943 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5903.09 | 0.9747 | 0.9456 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5903.09 | 0.8763 | 0.7351 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5903.09 | 0.6171 | 0.1895 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5903.09 | 0.0092 | -0.9871 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5903.09 | 0.0028 | -0.9964 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5904.092 | 0.8614 | 0.6924 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5904.092 | 0.9364 | 0.8581 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5904.092 | 0.8706 | 0.7126 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5904.092 | 0.9600 | 0.9105 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5904.092 | 1.0666 | 1.1497 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5904.092 | 0.8073 | 0.5738 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5904.092 | 0.5334 | -0.0105 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5904.092 | 0.0245 | -0.9685 | 0.8933 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5904.092 | 0.0044 | -0.9954 | 0.8933 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5905.091 | 0.9708 | 0.9356 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5905.091 | 1.0390 | 1.0865 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5905.091 | 1.0406 | 1.0900 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5905.091 | 1.0706 | 1.1566 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5905.091 | 1.0494 | 1.1095 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5905.091 | 0.9872 | 0.9717 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5905.091 | 0.8834 | 0.7439 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5905.091 | 0.0303 | -0.9582 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5905.091 | 0.0066 | -0.9923 | 0.9045 |